SG11201408123SA - Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof - Google Patents
Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereofInfo
- Publication number
- SG11201408123SA SG11201408123SA SG11201408123SA SG11201408123SA SG11201408123SA SG 11201408123S A SG11201408123S A SG 11201408123SA SG 11201408123S A SG11201408123S A SG 11201408123SA SG 11201408123S A SG11201408123S A SG 11201408123SA SG 11201408123S A SG11201408123S A SG 11201408123SA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- mechelen
- galapagos
- international
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663520P | 2012-06-22 | 2012-06-22 | |
| PCT/EP2013/061914 WO2013189771A1 (en) | 2012-06-22 | 2013-06-10 | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408123SA true SG11201408123SA (en) | 2015-01-29 |
Family
ID=48577773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408123SA SG11201408123SA (en) | 2012-06-22 | 2013-06-10 | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof |
| SG10201700125VA SG10201700125VA (en) | 2012-06-22 | 2013-06-10 | Aminotriazolopyridine For Use In The Treatment Of Inflammation, And Pharmaceutical Compositions Thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201700125VA SG10201700125VA (en) | 2012-06-22 | 2013-06-10 | Aminotriazolopyridine For Use In The Treatment Of Inflammation, And Pharmaceutical Compositions Thereof |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9284311B2 (ru) |
| EP (1) | EP2863950B1 (ru) |
| JP (2) | JP6238975B2 (ru) |
| KR (1) | KR102078069B1 (ru) |
| CN (2) | CN104379173A (ru) |
| AR (1) | AR091395A1 (ru) |
| AU (1) | AU2013279597B2 (ru) |
| BR (1) | BR112014031626A8 (ru) |
| CA (1) | CA2875619C (ru) |
| CL (1) | CL2014003462A1 (ru) |
| CO (1) | CO7160085A2 (ru) |
| CR (1) | CR20140583A (ru) |
| CY (1) | CY1120643T1 (ru) |
| DK (1) | DK2863950T3 (ru) |
| EA (1) | EA029084B1 (ru) |
| ES (1) | ES2685985T3 (ru) |
| HK (1) | HK1208368A1 (ru) |
| HR (1) | HRP20181364T8 (ru) |
| HU (1) | HUE038878T2 (ru) |
| IL (1) | IL235923B (ru) |
| LT (1) | LT2863950T (ru) |
| MA (1) | MA37775A1 (ru) |
| MX (1) | MX368511B (ru) |
| MY (1) | MY177334A (ru) |
| NZ (1) | NZ702480A (ru) |
| PE (1) | PE20150187A1 (ru) |
| PH (1) | PH12014502615B1 (ru) |
| PL (1) | PL2863950T3 (ru) |
| PT (1) | PT2863950T (ru) |
| SG (2) | SG11201408123SA (ru) |
| SI (1) | SI2863950T1 (ru) |
| TW (1) | TWI586352B (ru) |
| UA (1) | UA112804C2 (ru) |
| UY (1) | UY34855A (ru) |
| WO (1) | WO2013189771A1 (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| PL3283114T3 (pl) * | 2015-04-13 | 2024-01-03 | Galapagos Nv | Sposoby leczenia zaburzeń sercowo-naczyniowych |
| WO2016165953A1 (en) | 2015-04-13 | 2016-10-20 | Galapagos Nv | Methods for the treatment of inflammatory disorders |
| AU2016257892A1 (en) * | 2015-05-05 | 2017-11-09 | Concert Pharmaceuticals, Inc. | Deuterated filgotinib |
| CN105061420B (zh) * | 2015-06-04 | 2017-09-05 | 南京旗昌医药科技有限公司 | 一种jak抑制剂的晶型及其制备方法和应用 |
| WO2017106568A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer |
| US20170174788A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
| WO2017106564A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| CN112851682B (zh) * | 2016-02-02 | 2022-10-25 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡啶酰胺类化合物及其应用 |
| AU2017358703A1 (en) | 2016-11-10 | 2019-05-09 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
| GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201808575D0 (en) * | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| US20220185810A1 (en) * | 2019-03-30 | 2022-06-16 | Unichem Laboratories Limited | Novel Process for the Preparation of Filgotinib and Intermediates Thereof |
| JP7315166B2 (ja) * | 2019-06-10 | 2023-07-26 | 富士通株式会社 | グラフェンナノリボンネットワーク膜の製造方法及び電子装置の製造方法 |
| CN111686106B (zh) * | 2020-04-05 | 2022-07-15 | 温州医科大学附属第一医院 | 提高Dicer表达的化合物在制备药物中的应用 |
| CN114409675B (zh) * | 2022-01-07 | 2023-08-04 | 重庆医科大学 | 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007291190A1 (en) * | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| CN102459258B (zh) * | 2009-06-05 | 2015-11-25 | 赛福伦公司 | 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途 |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JO3030B1 (ar) * | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
-
2013
- 2013-06-10 MX MX2014014800A patent/MX368511B/es active IP Right Grant
- 2013-06-10 AR ARP130102033 patent/AR091395A1/es unknown
- 2013-06-10 CN CN201380032159.5A patent/CN104379173A/zh active Pending
- 2013-06-10 DK DK13727625.9T patent/DK2863950T3/en active
- 2013-06-10 AU AU2013279597A patent/AU2013279597B2/en active Active
- 2013-06-10 BR BR112014031626A patent/BR112014031626A8/pt not_active Application Discontinuation
- 2013-06-10 CN CN201810014031.0A patent/CN107998136A/zh active Pending
- 2013-06-10 MA MA37775A patent/MA37775A1/fr unknown
- 2013-06-10 EA EA201590071A patent/EA029084B1/ru unknown
- 2013-06-10 HU HUE13727625A patent/HUE038878T2/hu unknown
- 2013-06-10 ES ES13727625.9T patent/ES2685985T3/es active Active
- 2013-06-10 NZ NZ702480A patent/NZ702480A/en unknown
- 2013-06-10 PE PE2014002472A patent/PE20150187A1/es not_active Application Discontinuation
- 2013-06-10 CA CA2875619A patent/CA2875619C/en active Active
- 2013-06-10 JP JP2015517666A patent/JP6238975B2/ja active Active
- 2013-06-10 LT LTEP13727625.9T patent/LT2863950T/lt unknown
- 2013-06-10 UY UY0001034855A patent/UY34855A/es unknown
- 2013-06-10 KR KR1020157001521A patent/KR102078069B1/ko active IP Right Grant
- 2013-06-10 US US13/913,597 patent/US9284311B2/en active Active
- 2013-06-10 PT PT13727625T patent/PT2863950T/pt unknown
- 2013-06-10 SG SG11201408123SA patent/SG11201408123SA/en unknown
- 2013-06-10 PL PL13727625T patent/PL2863950T3/pl unknown
- 2013-06-10 MY MYPI2014703876A patent/MY177334A/en unknown
- 2013-06-10 EP EP13727625.9A patent/EP2863950B1/en active Active
- 2013-06-10 SG SG10201700125VA patent/SG10201700125VA/en unknown
- 2013-06-10 SI SI201331137T patent/SI2863950T1/sl unknown
- 2013-06-10 WO PCT/EP2013/061914 patent/WO2013189771A1/en active Application Filing
- 2013-06-11 TW TW102120793A patent/TWI586352B/zh active
- 2013-10-06 UA UAA201500458A patent/UA112804C2/uk unknown
-
2014
- 2014-11-24 PH PH12014502615A patent/PH12014502615B1/en unknown
- 2014-11-26 IL IL235923A patent/IL235923B/en active IP Right Grant
- 2014-12-16 CR CR20140583A patent/CR20140583A/es unknown
- 2014-12-19 CL CL2014003462A patent/CL2014003462A1/es unknown
- 2014-12-19 CO CO14279834A patent/CO7160085A2/es unknown
-
2015
- 2015-09-17 HK HK15109111.8A patent/HK1208368A1/xx unknown
-
2016
- 2016-03-14 US US15/069,130 patent/US20160296529A1/en not_active Abandoned
-
2017
- 2017-10-31 JP JP2017210372A patent/JP2018048185A/ja active Pending
-
2018
- 2018-08-27 HR HRP20181364TT patent/HRP20181364T8/hr unknown
- 2018-08-29 CY CY181100902T patent/CY1120643T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408123SA (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201901141WA (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201811490XA (en) | Cd3 binding antibodies | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201804118VA (en) | Compositions comprising bacterial strains | |
| SG11201408261UA (en) | Syringe | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201805941WA (en) | Tgfbeta 2 antibodies | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201407812SA (en) | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |